- Home
- CZNC vs ZURA Comparison
CZNC vs ZURA Comparison
Compare CZNC & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- ZURA
- Stock Information
- Founded
- CZNC 1864
- ZURA 2022
- Country
- CZNC United States
- ZURA United States
- Employees
- CZNC N/A
- ZURA N/A
- Industry
- CZNC Major Banks
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CZNC Finance
- ZURA Health Care
- Exchange
- CZNC Nasdaq
- ZURA Nasdaq
- Market Cap
- CZNC 312.9M
- ZURA 69.9M
- IPO Year
- CZNC N/A
- ZURA N/A
- Fundamental
- Price
- CZNC $20.02
- ZURA $2.00
- Analyst Decision
- CZNC
- ZURA Buy
- Analyst Count
- CZNC 0
- ZURA 10
- Target Price
- CZNC N/A
- ZURA $12.67
- AVG Volume (30 Days)
- CZNC 28.9K
- ZURA 341.9K
- Earning Date
- CZNC 10-16-2025
- ZURA 11-06-2025
- Dividend Yield
- CZNC 5.59%
- ZURA N/A
- EPS Growth
- CZNC 15.34
- ZURA N/A
- EPS
- CZNC 1.75
- ZURA N/A
- Revenue
- CZNC $108,310,000.00
- ZURA N/A
- Revenue This Year
- CZNC $5.72
- ZURA N/A
- Revenue Next Year
- CZNC $7.18
- ZURA N/A
- P/E Ratio
- CZNC $11.47
- ZURA N/A
- Revenue Growth
- CZNC 4.96
- ZURA N/A
- 52 Week Low
- CZNC $17.85
- ZURA $0.97
- 52 Week High
- CZNC $22.68
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- CZNC 52.62
- ZURA 55.46
- Support Level
- CZNC $19.78
- ZURA $1.97
- Resistance Level
- CZNC $20.45
- ZURA $2.19
- Average True Range (ATR)
- CZNC 0.40
- ZURA 0.14
- MACD
- CZNC -0.04
- ZURA -0.02
- Stochastic Oscillator
- CZNC 26.09
- ZURA 14.37
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.